https://doi.org/10.48047/AFJBS.6.12.2024.2422-2433

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

COMPUTATIONAL CHEMISTRY APPROACHES FOR DRUG DISCOVERY: ACCELERATING THE DESIGN AND OPTIMIZATION OF THERAPEUTICS

Dr. Devendra Pratap Singh
Assistant Professor, Dr.Ambedkar Institute of Technology for Handicapped, U.P. Awadhpuri, Kanpur

Rayudu Prasanthi
Assistant Professor, Department of ECE, Aditya College of Engineering and Technology, Surampalem

Dr. Shalini Sharma
Assistant Professor, Department of Chemistry, Medi-Caps University, Indore, M.P., India

Dr. A. Sreenivasa Rao
Lecturer, Department of Chemistry, Government Degree College (A) Tuni
District Kakinada, Andhra Pradesh, 533401

Dr. S. Mohamed Rabeek
Assistant Professor, PG and Research Department of Chemistry,
Jamal Mohamed College (Autonomous), Affiliated to Bharathidasan University, Trichy -20, Tamil Nadu

Dr. Sachin UmkantKalme
Department of Chemistry, Arts, Commerce & Science College, Gangakhed, Parbhani, Maharashtra

Article History
Volume 6, Issue 12, 2024
Received: 30 May 2024
Accepted : 30 June 2024
Doi:
10.48047/AFJBS.6.12.2024.2422-2433

Abstract

The field of computational chemistry has transformed the process of discovering new drugs by offering sophisticated techniques for designing and improving therapeutic treatments. This has resulted in a major increase in the speed of drug development and a reduction in expenses. These approaches include a range of methods such as molecular modelling, quantum chemistry, molecular dynamics simulations, and machine learning algorithms. Molecular docking and virtual screening enable researchers to anticipate the interactions between possible therapeutic candidates and biological targets, hence improving the identification of promising molecules. Quantum chemistry techniques offer in-depth understanding of electronic configurations and reaction processes, enabling the systematic creation of molecules with specific characteristics. Molecular dynamics simulations provide a dynamic perspective on the interactions between molecules and the changes in their shape and structure over time. This

enhances our comprehension of the binding of drugs to receptors and the stability of these interactions. Moreover, machine learning algorithms have the capability to analyse extensive information in order to identify trends and forecast biological activities, thereby facilitating the streamlining of lead chemical optimization. By incorporating these computational techniques, scientists may systematically investigate the range of chemical compounds, enhance the features related to the absorption, distribution, metabolism, and excretion of drugs, and anticipate any unintended effects on non-target molecules. This eventually accelerates the process of creating safer and more efficient treatments.

Keywords: *Computational Chemistry Drug Discovery Accelerating Design Optimization Therapeutics.*

1. INTRODUCTION

Computational methodologies have become fundamental for accelerating the tedious and costly course of drug discovery. The interaction is normally ordered into three essential stages: hit discovery, lead age, and lead optimization. The goal of the hit ID stage is to find substance intensifies that display good activity against a specific helpful objective, commonly a receptor or chemical. Structure-based drug design (SBDD) is used when there is admittance to underlying information of the objective, while ligand-based drug design (LBDD) is utilized in situations when there is an absence of or mistaken primary data. These strategies help in the ID of compound systems that cooperate well with the objective, bringing about a gainful pharmacological effect.



Figure 1: Drug discovery pipeline

Computational techniques aid in the exploration for small molecule inhibitors during hit discovery. SBDD utilizes intricate structural information about the target protein to develop inhibitors that accurately match the active site of the target. On the other hand, LBDD employs established active molecules to forecast new potential hits in situations when structural data is not accessible. These methods simplify the process of identifying initial findings that can be further improved. In the lead generation phase, the goal is to enhance the effectiveness of hit compounds against the target. In this phase, the utilization of advanced computational tools, such as free energy perturbation (FEP) calculations and molecular dynamics (MD) simulations, is essential. FEP calculations, enabled by high-performance CPU and GPU architectures, assisting in the improvement of potential drug candidates. Molecular dynamics (MD) simulations offer valuable information about the energy and rate of ligand binding. This helps to ensure that chemicals not only bind strongly, but also stay bound for a suitable amount of time, thereby enhancing their effectiveness in living organisms.

During the lead optimization phase, the lead compounds undergo refinement to transform them into drug-like molecules that possess optimal pharmacokinetic (PK) properties. This stage entails evaluating absorption, distribution, metabolism, excretion, and toxicity

(ADMET) factors to guarantee both effectiveness and safety. Computational techniques, such as quantitative structure-activity relationship (QSAR) models and chemometrics, are important tools for early prediction of ADMET characteristics. These methods assist in identifying compounds with the highest likelihood of clinical success.

The influence of computational chemistry on the process of finding new drugs has increased due to the advancement of quicker computer systems and improved problem-solving methods. Techniques such as CPU-intensive and GPU-based FEP calculations and conventional MD simulations are commonly employed for hit identification and lead creation. In recent times, there has been an increase in the accessibility of quantum mechanics (QM) and hybrid QM/MM approaches. This has facilitated in-depth investigations of covalent inhibitor interactions and has assisted in the exact customization of compounds to achieve high affinity. Notwithstanding progress, there are still numerous obstacles that persist. Attaining an ideal match between a novel molecule and its intended target is a multifaceted process that necessitates optimization beyond mere effectiveness. Computational approaches must also consider the physical factors that determine pharmacokinetic (PK) profiles. Early-stage ADMET prediction is essential for avoiding expensive failures in drug studies.

2. LITERATURE REVIEW

Madej et.al (2020). investigate how the AcceleratingTherapeutics for Opportunities in Medicine (ATOM) partnership has revolutionized the drug discovery process in their 2020 study. In order to accelerate the development of new treatments, this project represents a paradigm shift by combining multidisciplinary collaboration, artificial intelligence, and high-performance computers. The authors talk about the conventional problems in drug discovery—like long lead times and high attrition rates—and how ATOM seeks to solve them. They highlight the consortium's strategy for developing an all-encompassing, data-driven framework that makes better use of machine learning algorithms, advanced modelling approaches, and enormous volumes of biomedical data to forecast drug efficacy and safety profiles. ATOM seeks to drastically reduce the length of time needed for medication development from years to months by emphasizing quick hypothesis testing and iterative learning cycles. This study emphasizes how crucial it is for academic institutions, governmental organizations, and the pharmaceutical sector to work together to promote innovation and hasten the release of new medications for patients.

Sadybekov and Katritch(2023) offers a thorough examination of the most recent computational approaches that are transforming the drug discovery industry. They highlight how sophisticated algorithms and high-resolution structural data enable accurate drug-target interaction prediction. The paper also discusses how to validate and improve possible medication candidates by combining computational chemistry with experimental methods. The paper's explanation of the synergy between machine learning and conventional computational methods—which enables effective chemical space exploration and the identification of novel drug-like molecules—is one of its main highlights. Sadybekov and Katritch also discuss the drawbacks and restrictions of existing computational techniques, including the requirement for sizable, high-quality datasets and the high computational expense of precise simulations. They wrap up by summarizing upcoming initiatives and possible discoveries that could improve computational drug discovery's efficacy and efficiency even more.

Choudhuri et.al (2023). explore the latest developments in computational drug design made possible by machine learning and optimization techniques in their 2023 review that was published in Kinases and Phosphatases. The authors give a thorough explanation of how these cutting-edge computational methods are being used to improve drug discovery at every stage, from lead optimization to target identification. They talk about the creation of cutting-

edge machine learning models that can forecast drug candidates' binding affinities, spot possible side effects, and enhance pharmacokinetic characteristics. The article focuses on particular case studies wherein machine learning has shown effective in identifying potential medication candidates, which were subsequently confirmed through experimental trials. Furthermore, Choudhuri et al. investigate the incorporation of multi-objective optimization algorithms, which concurrently balance several pharmacological features and result in the creation of safer and more effective therapies. The authors also discuss the difficulties in applying machine learning to drug development, including the requirement for extensive and varied datasets and the interpretability of intricate models. They wrap up by talking about the potential applications of optimization and machine learning in the future for building more effective and focused drug discovery pipelines.

Duarte et.al (2019)Nanomedicine and Nanobiotechnology examines how computational methodologies can be integrated throughout the interrelated phases of target identification, drug discovery, and drug delivery. The authors contend that the effectiveness and success rate of the drug development process can be greatly increased by combining these stages in a holistic manner. They offer a thorough analysis of numerous computational techniques and tools, including molecular docking and dynamics for drug development, bioinformatics for target identification, and models based on nanotechnology for drug delivery. The review highlights the value of network pharmacology and systems biology in comprehending intricate biological processes and locating new targets for treatment. The authors also cover how medication candidates' pharmacokinetics and pharmacodynamics can be predicted by computational models, maximizing their transport to the intended place and reducing adverse effects. It is suggested that the combination of these computational methodologies can expedite the time to market and save costs by streamlining the entire drug development pipeline. In order to further improve the integration of target discovery, drug discovery, and drug delivery, Duarte et al. emphasize future approaches in computational drug discovery, including the use of artificial intelligence and big data analytics.

Cox and Gupta (2022) in ACS Medicinal Chemistry Letters offers a thorough analysis of the cutting-edge computational techniques and applications that are influencing modern drug discovery. The writers cover a broad spectrum of computational methods, emphasizing their individual functions in various phases of drug discovery. These methods include molecular docking, quantum mechanics, molecular dynamics simulations, and machine learning. They offer thorough explanations of a variety of software tools and platforms that are frequently used in the industry for drug design and optimization, including Auto Dock, Schrödinger Suite. The paper also discusses the use of computational techniques in personalized medicine, which uses patient-specific data to customize drug regimens to meet each patient's needs. Cox and Gupta stress the growing significance of high-performance computing resources and cloud computing in managing the massive computations needed for drug discovery. They also discuss issues like data interoperability and the requirement for established protocols that arise when merging computational tools with experimental methods. In order to increase the effectiveness and success rate of drug research, the authors conclude by outlining future trends in computational drug discovery, such as the growing usage of artificial intelligence and the creation of more precise and predictive models.

3. COMPUTATIONAL APPROACHES TO STRUCTURE-BASED DRUG DESIGN (SBDD)

Computational techniques in structure-based drug design (SBDD) use exact data about the designs of target proteins, normally got from high-goal X-beam crystallography or NMR information, to look at the collaborations with likely clever ligands. These strategies, pivotal for recognizing hits and propelling them to lead compounds, incorporate a scope of computational chemistry techniques including sub-atomic docking, traditional sub-atomic

elements (MD), Monte Carlo (MC) reenactments, and high-level quantum mechanics (QM)-based techniques. These strategies help in the production of particles that have a more noteworthy fascination and particularity for the ideal objective. Exploratory approval is important to demonstrate the adequacy of the recommended compounds as inhibitors. This features the cooperative part of drug discovery, where computational expectations and trial testing complete one another. This mix assists the most common way of creating strong drug applicants by offering significant comprehension of the cooperations among ligands and targets, and upgrading computational models through trial input.

4. FORCE FIELD-BASED METHODOLOGIES FOR STRUCTURE-BASED DRUG DESIGN (SBDD).

Computational techniques that depend on sub-atomic mechanics (MM) are fundamental in drug improvement as they consider the assessment of energy and different properties of sub-atomic frameworks. These techniques utilize force fields, which measure the expected energy of a framework by consolidating different elements that are changed in accordance with reflect exploratory or stomach muscle initio information. The power field condition integrates parts for both bound collaborations, (for example, substance securities, security points, and dihedral points) and nonbonded associations (counting van der Waals and electrostatic communications). Reinforced connections incorporate the compound securities framed between adjoining molecules, the points shaped by three iotas, and the dihedral points framed by four particles. These connections are portrayed utilizing quadratic and geometrical capabilities.

$$V = \underbrace{\sum_{\text{bonds}} K_R(R - R_{eq})^2 + \sum_{\text{angles}} K_\theta(\theta - \theta_{eq})^2 + \sum_{\text{dihedrals}} \frac{V_n}{2}[1 + \cos(n\phi - \gamma)]}_{\text{bonded interactions}} + \underbrace{\sum_{i<j}\left[\frac{A_{ij}}{R_{ij}^{12}} - \frac{B_{ij}}{R_{ij}^{6}} + \frac{q_i q_j}{\varepsilon R_{ij}}\right]}_{\text{non-bonded interactions}}$$

Lennard-Jones term (van der Waals interactions)

$$V_{vdW} = \sum_{i<j}\left[\frac{A_{ij}}{R_{ij}^{12}} - \frac{B_{ij}}{R_{ij}^{6}}\right]$$

Coulomb term (electrostatic interactions)

$$V_{el} = \sum_{i<j}\left[\frac{q_i q_j}{\varepsilon R_{ij}}\right]$$

The demonstrating of nonbonded communications includes the utilization of Lennard-Jones terms to address van der Waals powers and Coulomb terms to address electrostatic associations. Force fields like Golden, OPLS, GROMOS, and CHARMM are widely used for the investigation of biomolecular frameworks, including proteins, DNA, and RNA. There are additionally particular variants like GAFF and CgFF that are explicitly designed for researching drug-like natural mixtures. Force field-based techniques offer a huge benefit as far as handling proficiency when contrasted with quantum mechanics (QM)- based approaches. This makes them especially appropriate for enormous scope applications in drug improvement. These methodologies work with the ID of forthcoming inhibitors by supporting sub-atomic docking and virtual screening of huge compound libraries. They additionally empower once more drug design and old-style atomic elements recreations, which help in the productive creation and optimization of new treatments.

5. UTILIZING VIRTUAL SCREENING AND MOLECULAR DOCKING TECHNIQUES FOR THE PURPOSE OF DRUG DISCOVERY.

Virtual screening (VS) and sub-atomic docking are in many cases involved techniques in computational construction-based drug design (SBDD) to distinguish intensifies that productively tie to a particular protein pocket. These techniques are fundamental for recognizing promising hits and creating new leads. Assuming a particle can squeeze into a particular pocket in an objective, it is profoundly plausible that it will disturb the objective's

capability. This trademark makes it an entirely reasonable contender for the production of drugs. Float, GOLD, AUTODOCK, Moor, and ICM-Moor are broadly utilized mooring apparatuses that are utilized to proficiently look through broad assortments of little particles, which can arrive at millions in number, to distinguish new bioactive mixtures. Versus techniques help in the filtration of these assortments, bringing about more modest subsets of dynamic mixtures that are projected to have action against the objective. Generally, following an underlying screening, further developed docking methods are utilized to work on the exactness of the greatest scoring compounds, considering the adaptability of the receptor. After this stage, a visual assessment is commonly directed to limit the event of misleading up-sides. Misleading up-sides allude to intensifies that can possibly tie in unlikely compliances or at an extensive separation from the objective pocket. In the wake of being chosen, the mixtures are exposed to in vitro testing to check their action.



Figure 2: (a) Chart outlining the cooperation between a little particle ligand and the objective proteins. (b) The tight-fitting ligand #1, (R)- roscovitine, ties to cyclin-subordinate kinase-5 (CDK5). Extra ligands, explicitly ligands #2 to #4, are likewise shown.

CDK5 is a convincing pharmacological objective with the end goal of drug discovery. CDK5 dysregulation is related with different neurodegenerative circumstances, including Alzheimer's and Parkinson's problems, as well as amyotrophic parallel sclerosis. CDK5 is addressed utilizing lace models. The protein's dynamic site is portrayed as a sub-atomic surface, while a bunch of little ligand analogs with shifting compound qualities - ligands #1-4 - are shown in a space-filling portrayal. Unmistakable tones highlight the different traits of the four ligands

VS is dominatingly utilized for hit ID, with the goal of finding novel synthetic structures that display low inhibitory movement against the objective. These systems then, at that point, act as beginning layouts for the advancement of additional powerful inhibitors or leads. Hit compounds are normally found to have inhibitory portions (IC50) going from 10-100 micromolar, while lead compounds are recognized by their IC50 values in the low nanomolar range. Sub-atomic docking is significant in this technique since it predicts and surveys the associations among ligands and targets, precisely putting the ligand in the reactant site, and allocating an energy score to each posture. Docking computations comprise of two essential advances: situating the ligand inside the pocket and assessing the last posture. During the most common way of docking, conformational examining is completed to research the

possible restricting positions. This is accomplished utilizing methodical or deterministic hunts of rotatable bonds, mathematical complementarities, or further developed stochastic pursuits like Monte Carlo (MC) examining or transformative calculations. The scoring capabilities utilized for each stance are utilized to allot scores, and the mixtures are then arranged in light of their overall energy scores. The objective is for the best postures to match trial information intently.

The presenting and scoring stages are reliant, as the choice of the bound ligand's still up in the air by its energy score. Different scoring capabilities, going from force field-based to information-based possibilities, incorporate particular qualities and restrictions. Hence, it is important to fastidiously pick and assess them prior to leading a virtual screening effort. Every so often, an agreement score is produced by joining different scoring capabilities. To accomplish exact scoring in virtual screening (VS) and docking, it is important to handle issues connected with the suitable treatment of electrostatics, exact computation of desolvation energy, and joining of entropic impacts.



Figure 3: The virtual screening process starts by using a large compound collection, which is then subjected to virtual screening against a specific target.

Afterwards, the most advantageous ligands are subjected to in vitro experimentation, leading to the identification of hit compounds (characterized by an IC50 value of 100-10 mM, indicating 50% inhibition of the target). Ultimately, the hit compounds will undergo conversion into lead molecules, which possess enhanced inhibitory properties. Subsequently, these lead compounds will be subjected to in vivo testing to evaluate their efficacy and safety.

Taking into account the essential job of covered water particles in protein pockets, it is vital to recognize their capacity to upgrade ligand restricting. A critical obstruction is the semi static complementarity suspicion between the ligand and its objective, which might bring about the prohibition of essential hits as a result of restricted target adaptability. Present day upgrades in docking procedures currently empower the thought of various conformities of essential dynamic site deposits. Also, these calculations can incorporate sub-atomic elements (MD) reproductions or Monte Carlo (MC) searches to handle this issue actually. While unbending docking stays the essential strategy for dealing with enormous compound libraries, adaptable docking methods are progressively utilized to upgrade consistency and work on the exactness and outcome of computational drug advancement attempts.

6. COMPUTATIONAL DE NOVO DESIGN OF DRUG-LIKE MOLECULES

Computational once more drug design involves the age of new mixtures by developing them straightforwardly inside the limiting locale of the objective macromolecule, gradually gathering them. This methodology, like docking and virtual screening (VS), tries to research the scope of synthetic varieties and find synthetic substances that successfully match the objective hole and disturb its capability. Once more design programs, including BOMB, Manufacturer, Gen Star, and Show, give a scope of highlights to this particular goal. The design cycle initiates with brief seed, infrequently as little as a hydrogen particle, and utilizes ligand-developing or ligand-connecting systems to change over little pieces into individual drug-like atoms with a high expected proclivity for the objective.



Figure 4: The process of de novo ligand design involves constructing each chemical directly within the active site.

Ligand-developing is the most common way of connecting utilitarian gatherings to a focal section situated in the dynamic site. Then again, ligand-connecting incorporates combining various parts to frame a solitary particle. In this manner, these clever ligands go through optimization and scoring strategies that are tantamount to virtual screening (VS) and docking systems. Once more design offers a huge advantage in its ability to investigate a broad compound space, outperforming the impediments of current business libraries. It takes into account the examination of interesting designs and the distinguishing proof of promising platforms for additional optimization. By the by, this approach represents the possible risk of a combinatorial blast and multifaceted unpredictability while endeavoring to integrate the ideal particles. To handle these hardships, it is fitting to integrate limitations connected with the capacity to blend, and to support joint effort among computational and manufactured scientific experts. Anew design eventually further develops the hit recognizable proof stage by extending the scope of conceivable substance structures for prescription turn of events.

7. MOLECULAR DYNAMICS FOR SBDD

Traditional sub-atomic elements (MD) reproductions are essential in computational drug advancement because of their ability to show the fleeting movement of atomic frameworks utilizing Newtonian physical science. These recreations use force fields like Golden, OPLS-AA, and GROMOS, which give sensible depictions of the energetics of biomolecules,

including proteins and nucleic acids. These reenactments frequently incorporate express water conditions that are portrayed utilizing TIPnP. Atomic elements (MD) reenactments are profoundly significant during the time spent lead optimization. These reenactments decide the limiting free energies by considering the adaptability of the framework, the temperature, and the entropic impacts.



Figure 5: (a) portrays a regular sub-atomic elements (MD) model framework, outlining a protein drenched in unequivocal dissolvable.

CDK5 is bound to (R)- roscovitine within the sight of unequivocal water atoms [23]. (b) The MD reproduction steps frame a strategy to follow the progressions in unambiguous properties of a framework after some time. For instance, it tends to be utilized to quantify the root mean square deviation (RMSD) in Ångstroms of the whole protein and its dynamic site, comparative with the underlying X-beam structure.

They clarify the dynamic behavior of ligand-target complexes, such as FAAH, mAChRs, and ion channels, which is essential for comprehending medication effectiveness. MD also assesses the kinetics of binding, which includes measuring the residence periods in binding pockets (kon and koff). These factors have an impact on the stability and effectiveness of drugs. Advanced sampling techniques such as meta dynamics and free energy perturbation (FEP) enhance the ability of molecular dynamics (MD) to investigate infrequent biochemical events and accurately calculate intricate free energy landscapes. Although it is computationally expensive, molecular dynamics (MD) is still being used in drug design. This is due to advancements in algorithms and computational power, which allow for longer simulations and a better understanding of how drugs interact with their targets. These improvements are crucial for optimizing lead compounds in the drug discovery process.



Figure 6: Depicts A Schematic Representation ofa Thermodynamic Cycle Employed to Evaluate the Comparative Free Binding Energies of Ligand #1 And Ligand #2 To CDK5.

8. CONCLUSION

This paper emphasizes the crucial significance of computational chemistry methods in speeding up the process of discovering new drugs. It demonstrates how these methods are specifically applied at different stages of the drug development pipeline. Structure-based drug design (SBDD) approaches are very effective in identifying potential therapeutic candidates and generating lead compounds. This is achieved by carefully analyzing the interactions between the target protein and the ligand, leading to the production of highly powerful inhibitors. On the other hand, quantitative structure-activity relationship (QSAR) approaches are skilled at improving lead compounds to increase their drug-like qualities that are crucial for effectiveness and safety. These techniques are now being used in all stages of drug discovery. These methods allow for thorough investigation of molecular interactions, dynamics, and binding kinetics, which are essential for improving drug candidates. With the ongoing advancement of computational capabilities through faster hardware and algorithms, the future holds the potential for significant progress in speeding up drug development. This can be achieved by utilizing computational chemistry to drive the process of identifying, designing, and optimizing new therapies, ultimately leading to success in clinical applications.

REFERENCES

1. Brogi, S., Ramalho, T. C., Kuca, K., Medina-Franco, J. L., & Valko, M. (2020). In silico methods for drug design and discovery. *Frontiers in chemistry*, *8*, 612.
2. Choudhuri, S., Yendluri, M., Poddar, S., Li, A., Mallick, K., Mallik, S., & Ghosh, B. (2023). Recent advancements in computational drug design algorithms through machine learning and optimization. *Kinases and Phosphatases*, *1*(2), 117-140.
3. Cova, T. F., & Pais, A. A. (2019). Deep learning for deep chemistry: optimizing the prediction of chemical patterns. *Frontiers in chemistry*, *7*, 809.
4. Cox, P. B., & Gupta, R. (2022). Contemporary computational applications and tools in drug discovery. *ACS Medicinal Chemistry Letters*, *13*(7), 1016-1029.

5. Duarte, Y., Márquez-Miranda, V., Miossec, M. J., & González-Nilo, F. (2019). Integration of target discovery, drug discovery and drug delivery: a review on computational strategies. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, *11*(4), e1554.
6. Frye, L., Bhat, S., Akinsanya, K., & Abel, R. (2021). From computer-aided drug discovery to computer-driven drug discovery. *Drug Discovery Today: Technologies*, *39*, 111-117.
7. Gore, M., & Jagtap, U. B. (Eds.). (2018). *Computational drug discovery and design*. Humana Press.
8. Hinkson, I. V., Madej, B., & Stahlberg, E. A. (2020). Accelerating therapeutics for opportunities in medicine: a paradigm shift in drug discovery. *Frontiers in pharmacology*, *11*, 770.
9. Lin, X., Li, X., & Lin, X. (2020). A review on applications of computational methods in drug screening and design. *Molecules*, *25*(6), 1375.
10. Liu, X., IJzerman, A. P., & van Westen, G. J. (2020). Computational approaches for de novo drug design: past, present, and future. *Artificial neural networks*, 139-165.
11. Niazi, S. K., & Mariam, Z. (2023). Computer-aided drug design and drug discovery: a prospective analysis. *Pharmaceuticals*, *17*(1), 22.
12. Prieto-Martínez, F. D., López-López, E., Juárez-Mercado, K. E., & Medina-Franco, J. L. (2019). Computational drug design methods—current and future perspectives. *In silico drug design*, 19-44.
13. Rakesh Kumar Godi, Mule ShrishailBasvant, A Deepak, Arun Pratap Srivastava, Manoj Kumar, AkhilSankhyan, Anurag Shrivastava,Sentiment Analysis on Omicron Tweets Using Hybrid Classifiers with Multiple Feature Extraction Techniques and Transformer Based Models, International Journal of Intelligent Systems and Applications in Engineering, Vol-12, 15-S.
14. AyanBanik, JarabalaRanga, Anurag Shrivastava, Subash Ranjan Kabat, AVGA Marthanda, S Hemavathi,Novel Energy-Efficient Hybrid Green Energy Scheme for Future Sustainability, 2021 International Conference on Technological Advancements and Innovations (ICTAI)
15. Ajay Rana, Virender Khurana, Amit Shrivastava, DurgaprasadGangodkar, Deepika Arora, Anil Kumar Dixit,A ZEBRA Optimization Algorithm Search for Improving Localization in Wireless Sensor Network, 2022 2nd International Conference on Technological Advancements in Computational Sciences (ICTACS)
16. Balbir Singh, ManjushTatiya, Anurag Shrivastava, DevvretVerma, ArunPratap Srivastava, Ajay Rana, Detection of Alzheimer's Disease Using Deep Learning, Blockchain, and IoT Cognitive Data, 2022 2nd International Conference on Technological Advancements in Computational Sciences, ICTACS
17. Bikash Chandra Saha, Anurag Shrivastava, Sanjiv Kumar Jain, Prateek Nigam, S Hemavathi, On-Grid solar microgrid temperature monitoring and assessment in real time, Materials Today: Proceedings, Volume 62, Part 7, 2022.
18. ShamitaChakaborty, Yogini DilipBorole, Archana S Nanoty, Anurag Shrivastava, Sanjiv Kumar Jain, Moti Lal Rinawa,Smart Remote Solar Panel Cleaning Robot with Wireless Communication, 2021 9th International Conference on Cyber and IT Service Management (CITSM)
19. Schneider, G. (2018). Automating drug discovery. *Nature reviews drug discovery*, *17*(2), 97-113.

20. Wu, F., Zhou, Y., Li, L., Shen, X., Chen, G., Wang, X., ... & Huang, Z. (2020). Computational approaches in preclinical studies on drug discovery and development. *Frontiers in chemistry*, *8*, 726.
21. P William, NarendarChinthamu, Indradeep Kumar, Manish Gupta, Anurag Shrivastava, Arun Pratap Srivastava, Schema Design with Intelligent Multi Modelling Edge Computing Techniques for Industrial Applications**,** 2023 3rd International Conference on Pervasive Computing and Social Networking (ICPCSN).
22. Kuldeep Chouhan, Abhishek Singh, Anurag Shrivastava, Structural Support Vector Machine for Speech Recognition Classification with CNN Approach**,** 2021 9th International Conference on Cyber and IT Service Management (CITSM)**.**
23. A Deepak, P William, Rajat Dubey, Shilpa Sachdeva, C Vinotha, Sunny Masand, Anurag Shrivastava,Impact of Artificial Intelligence and Cyber Security as Advanced Technologies on Bitcoin Industries, International Journal of Intelligent Systems and Applications in Engineering, Vol-12, Issue-3.
24. Ajay Reddy Yeruva, Esraa Saleh Alomari, S Rashmi, Anurag Shrivastava, Routing in Ad Hoc Networks for Classifying and Predicting Vulnerabilities, Cybernetics and Systems, Taylor & Francis.
25. J. Prakash Arul Jose, Anurag Shrivastava, Prem Kumar Soni, N. Hemalatha,An Analysis of the Effects of Nanofluid-Based Serpentine Tube Cooling Enhancement in Solar Photovoltaic Cells for Green Cities, Hindawi, Journal of Nanomaterials Volume 2023,
26. Pooja Bagane, Susheel George Joseph, Abhishek Singh, Anurag Shrivastava, B Prabha, Amit Shrivastava,Classification of Malware using Deep Learning Techniques, 2021 9th International Conference on Cyber and IT Service Management (CITSM)
27. Shrivastava, A., Chakkaravarthy, M. , Shah, M.A.,Health Monitoring based Cognitive IoTusing Fast Machine Learning Technique. In International Journal of Intelligent Systemsand Applications in Engineering, 2023, 11(6s), pp. 720–729
28. Shrivastava, A. , Chakkaravarthy, M. , Shah, M.A..A Novel Approach Using Learning Algorithm for Parkinson's Disease Detectionwith Handwritten Sketches. In Cybernetics and Systems, 2022
29. Shrivastava, A., Chakkaravarthy, M. , Shah, M.A., A new machine learning method for predicting systolic and diastolic blood pressureusing clinical characteristics. In Healthcare Analytics, 2023, 4, 100219
30. Shrivastava, A., Rajput, N., Rajesh, P., Swarnalatha, S.R., IoT-Based Label Distribution Learning Mechanism for Autism SpectrumDisorder for Healthcare Application. In Practical Artificial Intelligence for Internet of Medical Things: Emerging Trends, Issues, andChallenges, 2023, pp. 305–321